Multiple/JJ
Group/NN
Testing/JJ
Procedures/NNS
for/IN
Analysis/NN
of/IN
High-Dimensional/JJ
Genomic/JJ
Data/NNS
./.
====================
In/IN
genetic/JJ
association/NN
studies/NNS
with/IN
high-dimensional/JJ
genomic/JJ
data/NNS
,/,
multiple/JJ
group/NN
testing/VBG
procedures/NNS
are/VBP
often/RB
required/VBN
in/IN
order/NN
to/TO
identify/VB
disease/trait-related/JJ
genes/NNS
or/CC
genetic/JJ
regions/NNS
,/,
where/WRB
multiple/JJ
genetic/JJ
sites/NNS
or/CC
variants/NNS
are/VBP
located/JJ
within/IN
the/DT
same/JJ
gene/NN
or/CC
genetic/JJ
region/NN
./.
====================
However/RB
,/,
statistical/JJ
testing/NN
procedures/NNS
based/VBN
on/IN
an/DT
individual/JJ
test/NN
suffer/VBP
from/IN
multiple/JJ
testing/VBG
issues/NNS
such/JJ
as/IN
the/DT
control/NN
of/IN
family-wise/JJ
error/NN
rate/NN
and/CC
dependent/JJ
tests/NNS
./.
====================
Moreover/RB
,/,
detecting/VBG
only/RB
a/DT
few/JJ
of/IN
genes/NNS
associated/VBN
with/IN
a/DT
phenotype/NN
outcome/NN
among/IN
tens/NNS
of/IN
thousands/NNS
of/IN
genes/NNS
is/VBZ
of/IN
main/JJ
interest/NN
in/IN
genetic/JJ
association/NN
studies/NNS
./.
====================
In/IN
this/DT
reason/NN
regularization/NN
procedures/NNS
,/,
where/WRB
a/DT
phenotype/NN
outcome/NN
regresses/VBZ
on/IN
all/DT
genomic/JJ
markers/NNS
and/CC
then/RB
regression/NN
coefficients/NNS
are/VBP
estimated/VBN
based/VBN
on/IN
a/DT
penalized/JJ
likelihood/JJ
,/,
have/VBP
been/VBN
considered/VBN
as/IN
a/DT
good/JJ
alternative/JJ
approach/NN
to/TO
analysis/NN
of/IN
high-dimensional/JJ
genomic/JJ
data/NNS
./.
====================
But/CC
,/,
selection/NN
performance/NN
of/IN
regularization/NN
procedures/NNS
has/VBZ
been/VBN
rarely/RB
compared/VBN
with/IN
that/DT
of/IN
statistical/JJ
group/NN
testing/NN
procedures/NNS
./.
====================
In/IN
this/DT
article/NN
,/,
we/PRP
performed/VBD
extensive/JJ
simulation/NN
studies/NNS
where/WRB
commonly/RB
used/VBN
group/NN
testing/VBG
procedures/NNS
such/JJ
as/IN
principal/JJ
component/NN
analysis/NN
,/,
Hotelling/JJ
's/POS
T2/NN
test/NN
,/,
and/CC
permutation/NN
test/NN
are/VBP
compared/VBN
with/IN
group/NN
lasso/RB
(/(
least/JJS
absolute/JJ
selection/NN
and/CC
shrinkage/JJ
operator/NN
)/)
in/IN
terms/NNS
of/IN
true/JJ
positive/JJ
selection/NN
./.
====================
Also/RB
,/,
we/PRP
applied/VBD
all/DT
methods/NNS
considered/VBN
in/IN
simulation/JJ
studies/NNS
to/TO
identify/VB
genes/NNS
associated/VBN
with/IN
ovarian/JJ
cancer/NN
from/IN
over/IN
20,000/CD
genetic/JJ
sites/NNS
generated/VBN
from/IN
Illumina/NN
Infinium/NN
HumanMethylation27K/JJ
Beadchip/NN
./.
====================
We/PRP
found/VBD
a/DT
big/NN
discrepancy/NN
of/IN
selected/VBN
genes/NNS
between/IN
multiple/JJ
group/NN
testing/NN
procedures/NNS
and/CC
group/NN
lasso/RB
./.
====================
In/IN
human/JJ
genetic/JJ
association/NN
studies/NNS
with/IN
high-dimensional/JJ
genomic/JJ
data/NNS
,/,
a/DT
multiple/JJ
group/NN
testing/VBG
procedure/NN
is/VBZ
often/RB
required/VBN
to/TO
identify/VB
genes/NNS
or/CC
genetic/JJ
regions/NNS
that/IN
are/VBP
associated/VBN
with/IN
a/DT
disease/NN
or/CC
a/DT
trait/JJ
since/IN
a/DT
gene/NN
or/CC
a/DT
genetic/JJ
region/NN
usually/RB
contains/VBZ
multiple/JJ
genetic/JJ
sites/NNS
or/CC
variants/NNS
./.
====================
For/IN
instance/NN
,/,
single/JJ
nucleotide/NN
polymorphism/NN
data/NNS
,/,
DNA/NN
methylation/NN
data/NNS
and/CC
sequencing/NN
data/NNS
consist/VBP
of/IN
tens/NNS
of/IN
thousands/NNS
of/IN
genes/NNS
where/WRB
each/DT
gene/NN
has/VBZ
multiple/JJ
genetic/JJ
sites/NNS
./.
====================
In/IN
order/NN
to/TO
identify/VB
genes/NNS
or/CC
genetic/JJ
regions/NNS
associated/VBN
with/IN
a/DT
phenotype/NN
outcome/NN
,/,
we/PRP
need/VBD
to/TO
conduct/VB
an/DT
individual/JJ
group/NN
test/NN
for/IN
each/DT
gene/NN
./.
====================
However/RB
,/,
an/DT
individual/JJ
test/NN
for/IN
high-dimensional/JJ
genomic/JJ
data/NNS
suffers/VBZ
from/IN
multiple/JJ
testing/VBG
issues/NNS
such/JJ
as/IN
the/DT
control/NN
of/IN
family-wise/JJ
error/NN
rate/NN
(/(
FWER/NN
)/)
or/CC
dependent/JJ
tests/NNS
./.
====================
In/IN
this/DT
reason/NN
,/,
Bonferroni/NNP
adjustment/JJ
or/CC
false/VBP
discovery/NN
rate/NN
(/(
FDR/NN
)/)
control/NN
methods/NNS
[/(
123/CD
]/)
should/MD
be/VB
performed/VBN
after/IN
computing/VBG
the/DT
p-value/JJ
of/IN
a/DT
multiple/JJ
group/NN
test/NN
for/IN
individual/JJ
genes/NNS
or/CC
genetic/JJ
regions/NNS
./.
====================
Alternatively/RB
,/,
regularization/NN
procedures/NNS
using/VBG
a/DT
penalized/JJ
likelihood/NN
can/MD
be/VB
applied/VBN
for/IN
analysis/NN
of/IN
high-dimensional/JJ
genomic/JJ
data/NNS
./.
====================
Basically/RB
,/,
regularization/NN
procedures/NNS
perform/NN
variable/JJ
selection/NN
based/VBN
on/IN
a/DT
parametric/JJ
regression/NN
with/IN
a/DT
penalty/NN
function/NN
,/,
where/WRB
a/DT
phenotype/NN
outcome/NN
regresses/VBZ
on/IN
all/DT
of/IN
genetic/JJ
sites/NNS
./.
====================
As/IN
a/DT
tuning/JJ
parameter/NN
for/IN
sparsity/NN
is/VBZ
decreasing/VBG
,/,
the/DT
most/JJS
outcome-related/JJ
genetic/JJ
sites/NNS
can/MD
be/VB
sequentially/RB
selected/VBN
./.
====================
One/CD
of/IN
the/DT
most/JJS
popular/JJ
regularization/NN
procedures/NNS
for/IN
high-dimensional/JJ
genomic/JJ
data/NNS
is/VBZ
lasso/RB
(/(
least/JJS
absolute/JJ
shrinkage/NN
and/CC
selection/NN
operator/NN
)/)
[/(
456/CD
]/)
./.
====================
For/IN
group/NN
selection/NN
such/JJ
as/IN
a/DT
gene/NN
or/CC
a/DT
genetic/JJ
region/NN
,/,
group/NN
lasso/RB
can/MD
be/VB
applied/VBN
to/TO
high-dimensional/JJ
genomic/JJ
data/NNS
that/IN
has/VBZ
a/DT
group/NN
or/CC
a/DT
cluster/NN
structure/NN
[/(
78/CD
]/)
./.
====================
Since/IN
regularization/NN
procedures/NNS
do/VBP
not/RB
test/VB
but/CC
select/JJ
a/DT
gene/NN
or/CC
a/DT
genetic/JJ
region/NN
associated/VBN
with/IN
a/DT
phenotype/NN
outcome/NN
,/,
the/DT
control/NN
of/IN
FWER/NN
or/CC
FDR/NN
is/VBZ
not/RB
required/VBN
./.
====================
However/RB
,/,
the/DT
selection/NN
of/IN
the/DT
optimal/JJ
tuning/NN
parameter/NN
is/VBZ
crucial/JJ
to/TO
determine/VB
the/DT
number/NN
of/IN
the/DT
outcome-related/JJ
genes/NNS
or/CC
genetic/JJ
regions/NNS
./.
====================
The/DT
main/JJ
goal/NN
of/IN
both/DT
the/DT
individual/JJ
group/NN
test/NN
and/CC
the/DT
group/NN
selection/NN
procedure/NN
is/VBZ
to/TO
identify/VB
disease/trait-related/JJ
genes/NNS
or/CC
genetic/JJ
regions/NNS
in/IN
analysis/NN
of/IN
high-dimensional/JJ
genomic/JJ
data/NNS
./.
====================
Although/IN
these/DT
two/CD
different/JJ
statistical/JJ
methods/NNS
have/VBP
the/DT
same/JJ
goal/NN
,/,
there/EX
have/VBP
been/VBN
rarely/RB
statistical/JJ
literatures/NNS
which/WDT
compare/VBP
either/CC
test/NN
performance/IN
or/CC
selection/NN
performance/NN
of/IN
two/CD
statistical/JJ
methods/NNS
since/IN
hypothesis/NN
testing/VBG
and/CC
variable/JJ
selection/NN
have/VBP
been/VBN
considered/VBN
as/IN
completely/RB
different/JJ
approaches/NNS
in/IN
statistics/NNS
./.
====================
In/IN
genetic/JJ
association/NN
studies/NNS
,/,
however/RB
,/,
the/DT
testing/NN
procedure/NN
essentially/RB
determines/VBZ
whether/IN
each/DT
gene/NN
or/CC
each/DT
genetic/JJ
region/NN
is/VBZ
significantly/RB
associated/VBN
with/IN
a/DT
phenotype/NN
outcome/NN
or/CC
not/RB
,/,
while/IN
variable/JJ
selection/NN
makes/VBZ
a/DT
conclusion/NN
which/WDT
genes/NNS
or/CC
genetic/JJ
regions/NNS
are/VBP
associated/VBN
with/IN
a/DT
phenotype/NN
outcome/NN
./.
====================
Therefore/RB
,/,
we/PRP
can/MD
directly/RB
compare/VB
the/DT
true/JJ
positives/VBZ
of/IN
the/DT
group/NN
test/NN
procedure/NN
and/CC
the/DT
group/NN
selection/NN
procedure/NN
when/WRB
they/PRP
identify/VBP
the/DT
same/JJ
number/NN
of/IN
disease/trait-related/JJ
genes/NNS
or/CC
genetic/JJ
regions/NNS
./.
====================
In/IN
this/DT
article/NN
,/,
we/PRP
conduct/VBP
extensive/JJ
simulation/NN
studies/NNS
in/IN
order/NN
to/TO
compare/VB
the/DT
performance/NN
of/IN
both/DT
group/NN
testing/NN
procedures/NNS
and/CC
group/NN
selection/NN
procedure/NN
in/IN
terms/NNS
of/IN
true/JJ
positives/VBZ
./.
====================
That/DT
is/VBZ
,/,
the/DT
total/JJ
number/NN
of/IN
correctly/RB
identified/VBN
genes/NNS
or/CC
genetic/JJ
regions/NNS
is/VBZ
compared/VBN
when/WRB
the/DT
same/JJ
number/NN
of/IN
genes/NNS
or/CC
genetic/JJ
regions/NNS
is/VBZ
detected/VBN
./.
====================
The/DT
simulation/JJ
studies/NNS
focus/VBP
on/IN
a/DT
case-control/JJ
association/NN
study/NN
with/IN
high-dimensional/JJ
genomic/JJ
data/NNS
which/WDT
has/VBZ
a/DT
group/NN
or/CC
a/DT
cluster/NN
structure/NN
./.
====================
For/IN
group/NN
testing/NN
procedures/NNS
,/,
we/PRP
consider/VBP
commonly/RB
used/VBN
three/CD
methods/NNS
such/JJ
as/IN
principal/JJ
component/NN
analysis/NN
(/(
PCA/NN
)/)
,/,
Hotelling/JJ
's/POS
T2/NN
test/NN
,/,
and/CC
permutation/NN
test/NN
./.
====================
For/IN
group/NN
selection/NN
procedure/NN
,/,
we/PRP
employ/VBP
group/NN
lasso/RB
./.
====================
These/DT
four/CD
statistical/JJ
methods/NNS
are/VBP
also/RB
applied/VBD
to/TO
real/JJ
high-dimensional/JJ
DNA/NN
methylation/NN
data/NNS
where/WRB
DNA/NN
methylation/NN
beta/NN
values/NNS
of/IN
CpG/NN
sites/NNS
from/IN
approximately/RB
12,000/CD
genes/NNS
between/IN
ovarian/JJ
cancer/NN
cases/NNS
and/CC
healthy/JJ
controls/NNS
were/VBD
generated/VBN
from/IN
Illumina/NN
Infinium/NN
Human-Methylation27K/NNP
Beadchip/NN
(/(
Illumina/NN
Inc./NNP
,/,
San/NNP
Diego/JJ
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
Principal/JJ
component/NN
analysis/NN
====================
PCA/NN
is/VBZ
one/CD
of/IN
the/DT
most/JJS
common/JJ
statistical/JJ
approaches/NNS
to/TO
data/NNS
dimension/NN
reduction/NN
[/(
9/CD
]/)
./.
====================
It/PRP
basically/RB
transforms/VBZ
multiple/JJ
variables/NNS
to/TO
have/VB
orthogonality/NN
so/RB
the/DT
first/JJ
principal/JJ
component/NN
can/MD
be/VB
expressed/VBN
as/IN
a/DT
weighted/JJ
linear/JJ
combination/NN
of/IN
variables/NNS
./.
====================
The/DT
weights/NNS
of/IN
the/DT
first/JJ
component/NN
are/VBP
computed/VBN
such/JJ
that/IN
the/DT
component/NN
can/MD
account/VB
for/IN
the/DT
greatest/JJS
possible/JJ
variance/NN
of/IN
multiple/JJ
variables/NNS
./.
====================
In/IN
case-control/JJ
association/NN
studies/NNS
of/IN
genomic/JJ
data/NNS
with/IN
a/DT
group/NN
structure/NN
,/,
we/PRP
can/MD
apply/RB
PCA/NN
for/IN
each/DT
gene/NN
or/CC
genetic/JJ
region/NN
,/,
where/WRB
data/NNS
information/NN
of/IN
multiple/JJ
genetic/JJ
sites/NNS
within/IN
the/DT
same/JJ
gene/NN
or/CC
genetic/JJ
region/NN
can/MD
be/VB
reduced/VBN
to/TO
a/DT
single/JJ
numerical/JJ
vector/NN
corresponding/VBG
to/TO
the/DT
first/JJ
principal/JJ
component/NN
./.
====================
Then/RB
,/,
a/DT
phenotypic/JJ
association/NN
of/IN
the/DT
principal/JJ
component/NN
can/MD
be/VB
tested/VBN
based/VBN
on/IN
the/DT
independent/JJ
two/CD
sample/JJ
T-test/JJS
./.
====================
Statistical/JJ
approaches/NNS
based/VBN
on/IN
PCA/NN
have/VBP
been/VBN
widely/RB
applied/VBN
to/TO
analysis/NN
of/IN
high-dimensional/JJ
genomic/JJ
data/NNS
[/(
101112/CD
]/)
./.
====================
Hotelling/VBG
's/POS
T2/NN
test/NN
====================
Hotelling/VBG
's/POS
T2/NN
test/NN
is/VBZ
one/CD
of/IN
the/DT
representative/JJ
multivariate/JJ
tests/NNS
used/VBN
when/WRB
significant/JJ
differences/NNS
between/IN
the/DT
mean/JJ
vectors/NNS
of/IN
two/CD
multivariate/JJ
data/NNS
sets/NNS
are/VBP
tested/VBN
./.
====================
It/PRP
is/VBZ
known/VBN
as/IN
a/DT
powerful/JJ
multivariate/JJ
test/NN
as/IN
long/JJ
as/IN
data/NNS
satisfies/NNS
necessary/JJ
assumptions/NNS
such/JJ
as/IN
random/JJ
samples/NNS
,/,
multivariate/JJ
normality/NN
and/CC
equivalent/JJ
variance/NN
and/CC
covariance/NN
matrices/NNS
between/IN
two/CD
groups/NNS
./.
====================
In/IN
genetic/JJ
association/NN
studies/NNS
with/IN
microarray/NN
data/NNS
,/,
the/DT
Hotelling/JJ
's/POS
T2/NN
test/NN
is/VBZ
often/RB
applied/VBN
to/TO
find/VB
differentially/RB
expressed/VBN
genes/NNS
[/(
1314/CD
]/)
./.
====================
We/PRP
also/RB
applied/VBD
the/DT
Hotelling/JJ
's/POS
T2/NN
test/NN
for/IN
each/DT
gene/NN
or/CC
genetic/JJ
region/NN
to/TO
test/VB
a/DT
significant/JJ
difference/NN
between/IN
cases/NNS
and/CC
controls/VBZ
./.
====================
We/PRP
employed/VBD
an/DT
R/NN
package/NN
‘/CD
Hotelling/JJ
’/CD
for/IN
simulation/JJ
studies/NNS
and/CC
real/JJ
data/NNS
analysis/NN
./.
====================
Permutation/NN
test/NN
====================
Permutation/NN
test/NN
is/VBZ
a/DT
nonparametric/JJ
statistical/JJ
test/NN
used/VBN
when/WRB
an/DT
underlying/VBG
distribution/NN
of/IN
genetic/JJ
data/NNS
is/VBZ
not/RB
need/VBN
to/TO
be/VB
assumed/VBN
./.
====================
If/IN
the/DT
derivation/NN
of/IN
a/DT
theoretical/JJ
distribution/NN
of/IN
a/DT
test/NN
statistic/JJ
is/VBZ
challenging/JJ
,/,
permutation/NN
test/NN
can/MD
be/VB
employed/VBN
to/TO
compute/VB
an/DT
empirical/JJ
p-value/NN
of/IN
the/DT
test/NN
statistic/JJ
./.
====================
For/IN
genomic/JJ
data/NNS
with/IN
a/DT
group/NN
structure/NN
,/,
we/PRP
first/RB
compute/JJ
an/DT
individual/JJ
p-value/NN
of/IN
a/DT
phenotypic/JJ
association/NN
test/NN
for/IN
each/DT
genetic/JJ
site/NN
./.
====================
We/PRP
then/RB
combine/VBP
K/NN
p-values/NNS
such/JJ
that/IN
–∑i=1Klogpi/NN
,/,
where/WRB
pi/NN
is/VBZ
the/DT
p-value/JJ
of/IN
the/DT
the/DT
i-th/NN
genetic/JJ
site/NN
,/,
and/CC
K/NN
is/VBZ
the/DT
total/JJ
number/NN
of/IN
genetic/JJ
sites/NNS
in/IN
the/DT
gene/NN
or/CC
genetic/JJ
region/NN
./.
====================
Next/RB
,/,
we/PRP
repeatedly/RB
permute/JJ
case-control/JJ
labels/NNS
and/CC
compute/VBP
–∑i=1Klogpi/NN
for/IN
each/DT
permutation/NN
set/NN
./.
====================
After/IN
we/PRP
obtain/VBP
the/DT
empirical/JJ
distribution/NN
of/IN
–∑i=1Klogpi/NN
,/,
we/PRP
can/MD
easily/RB
calculate/JJ
the/DT
empirical/JJ
p-value/NN
from/IN
the/DT
original/JJ
case/NN
and/CC
control/NN
set/NN
./.
====================
This/DT
permutation/NN
based/VBN
test/NN
for/IN
genomic/JJ
data/NNS
with/IN
a/DT
group/NN
structure/NN
has/VBZ
been/VBN
demonstrated/VBN
to/TO
be/VB
very/RB
efficient/JJ
and/CC
powerful/JJ
when/WRB
we/PRP
need/VBD
to/TO
aggregate/VB
the/DT
information/NN
of/IN
multiple/JJ
genetic/JJ
sites/NNS
[/(
15/CD
]/)
./.
====================
Group/NN
lasso/RB
====================
Statistical/JJ
association/NN
tests/NNS
above/IN
should/MD
be/VB
conducted/VBN
to/TO
each/DT
gene/NN
or/CC
each/DT
genetic/JJ
region/NN
one/CD
at/IN
a/DT
time/NN
,/,
so/RB
the/DT
individual/JJ
tests/NNS
can/MD
not/RB
consider/VB
genetic/JJ
correlations/NNS
among/IN
genes/NNS
./.
====================
But/CC
,/,
genes/NNS
linked/VBN
with/IN
each/DT
other/JJ
on/IN
genetic/JJ
pathways/NNS
or/CC
genes/NNS
that/WDT
have/VBP
an/DT
interaction/NN
effects/NNS
on/IN
a/DT
phenotype/NN
outcome/NN
can/MD
have/VB
a/DT
functional/JJ
relationship/NN
with/IN
each/DT
other/JJ
./.
====================
Since/IN
their/PRP$
correlations/NNS
could/MD
be/VB
important/JJ
information/NN
for/IN
genetic/JJ
association/NN
studies/NNS
,/,
a/DT
statistical/JJ
model/NN
that/DT
can/MD
includes/VBZ
all/DT
of/IN
genetic/JJ
information/NN
is/VBZ
often/RB
preferred/VBN
./.
====================
Regularization/NN
procedures/NNS
can/MD
be/VB
conducted/VBN
to/TO
entire/VB
genomes/NNS
in/IN
a/DT
regression/NN
framework/NN
,/,
where/WRB
a/DT
phenotype/NN
outcome/NN
is/VBZ
regressed/VBN
on/IN
all/DT
of/IN
genetic/JJ
data/NNS
./.
====================
The/DT
solution/NN
of/IN
regression/NN
coefficients/NNS
can/MD
be/VB
achieved/VBN
,/,
constraining/VBG
the/DT
parameter/NN
space/NN
of/IN
regression/NN
coefficients/NNS
./.
====================
This/DT
constraint/NN
actually/RB
enables/VBZ
to/TO
obtain/VB
the/DT
coefficient/JJ
solution/NN
even/RB
if/IN
the/DT
number/NN
of/IN
genes/NNS
is/VBZ
much/RB
greater/JJR
than/IN
a/DT
sample/JJ
size/NN
./.
====================
Depending/VBG
on/IN
the/DT
parameter/NN
space/NN
constraint/NN
,/,
a/DT
type/NN
of/IN
regularization/NN
procedure/NN
is/VBZ
determined/VBN
./.
====================
Group/NN
lasso/RB
regularizes/VBZ
regression/NN
coefficients/NNS
such/JJ
that/IN
the/DT
sum/NN
of/IN
L2/NN
norm/NN
of/IN
the/DT
coefficients/NNS
for/IN
each/DT
group/NN
is/VBZ
less/RBR
than/IN
an/DT
arbitrary/JJ
value/NN
[/(
7/CD
]/)
./.
====================
The/DT
arbitrary/JJ
value/NN
is/VBZ
corresponding/JJ
to/TO
a/DT
tuning/JJ
parameter/NN
value/NN
for/IN
sparsity/NN
./.
====================
For/IN
a/DT
fixed/JJ
tuning/VBG
parameter/NN
λ/RB
,/,
the/DT
estimated/VBN
regression/JJ
coefficients/NNS
β=/RB
(/(
β1/LS
,/,
β2/RB
,/,
…/NNP
,/,
βm/RB
)/)
T/NN
of/IN
group/NN
lasso/RB
maximizes/VBZ
Qλβ=/NNP
−lβ+λ∑k=1mmkβk2/NN
,/,
where/WRB
l/JJ
(/(
β/RB
)/)
is/VBZ
a/DT
logistic/JJ
likelihood/JJ
,/,
and/CC
mk/RB
is/VBZ
the/DT
total/JJ
number/NN
of/IN
genetic/JJ
sites/NNS
of/IN
the/DT
k-th/JJ
gene/NN
,/,
i.e./FW
,/,
βk=/RB
(/(
βk1/NN
,/,
βk2/RB
,/,
…/NNP
,/,
βkmk/RB
)/)
T./FW
The/DT
L2/NN
norm/CC
of/IN
βk/JJ
is/VBZ
defined/VBN
as/IN
βk2=/RB
∑j=1mkβkj2/NN
./.
====================
In/IN
genomic/JJ
data/NNS
analysis/NN
with/IN
a/DT
group/NN
structure/NN
,/,
group/NN
lasso/RB
sequentially/RB
selects/NNS
the/DT
most/JJS
outcome-related/VBN
gene/NN
or/CC
genetic/JJ
region/NN
./.
====================
The/DT
selection/NN
results/VBZ
rely/RB
on/IN
the/DT
tuning/JJ
parameter/NN
value/NN
λ/RB
since/IN
we/PRP
have/VBP
different/JJ
coefficient/JJ
estimates/NNS
for/IN
a/DT
value/NN
of/IN
λ/JJ
./.
====================
As/IN
λ/RB
decreases/VBZ
,/,
the/DT
number/NN
of/IN
selected/VBN
genes/NNS
is/VBZ
gradually/RB
increased/VBD
./.
====================
In/IN
general/JJ
,/,
we/PRP
select/VBP
the/DT
k-th/NN
gene/NN
if/IN
the/DT
estimated/VBN
regression/NN
coefficients/NNS
βk/NN
are/VBP
nonzero/JJ
./.
====================
In/IN
group/NN
lasso/RB
,/,
the/DT
estimated/VBN
regression/NN
coefficients/NNS
of/IN
all/DT
genetic/JJ
sites/NNS
belong/IN
to/TO
selected/VBN
genes/NNS
or/CC
genetic/JJ
regions/NNS
are/VBP
nonzero/JJ
while/IN
all/DT
genetic/JJ
sites/NNS
of/IN
unselected/JJ
genes/NNS
or/CC
genetic/JJ
regions/NNS
have/VBP
the/DT
exactly/RB
zero/CD
regression/NN
coefficients/NNS
./.
====================
Therefore/RB
,/,
group/NN
selection/NN
can/MD
be/VB
performed/VBN
based/VBN
on/IN
the/DT
solution/NN
of/IN
regression/NN
coefficients/NNS
for/IN
a/DT
fixed/JJ
value/NN
of/IN
λ/JJ
./.
====================
Note/RB
that/DT
the/DT
numerical/JJ
values/NNS
of/IN
estimated/VBN
coefficients/NNS
βk/NN
are/VBP
not/RB
of/IN
interest/NN
since/IN
group/NN
lasso/RB
performs/NNS
selection/NN
but/CC
not/RB
prediction/NN
./.
====================
That/DT
is/VBZ
,/,
we/PRP
see/VBP
if/IN
βk/NN
=/JJ
0/CD
or/CC
not/RB
./.
====================
In/IN
our/PRP$
simulation/NN
studies/NNS
and/CC
real/JJ
data/NNS
analysis/NN
,/,
we/PRP
first/RB
started/VBD
with/IN
a/DT
relatively/RB
large/JJ
λ/JJ
value/NN
which/WDT
is/VBZ
large/JJ
enough/IN
that/DT
the/DT
solution/NN
to/TO
all/DT
regression/NN
coefficients/NNS
can/MD
be/VB
exactly/RB
zero/CD
./.
====================
In/IN
this/DT
case/NN
,/,
no/DT
genes/NNS
are/VBP
selected/VBN
./.
====================
We/PRP
then/RB
gradually/RB
decreased/VBD
the/DT
value/NN
of/IN
λ/JJ
until/IN
a/DT
single/JJ
gene/NN
has/VBZ
nonzero/JJ
regression/NN
coefficients/NNS
of/IN
its/PRP$
genetic/JJ
sites/NNS
./.
====================
This/DT
gene/NN
is/VBZ
considered/VBN
as/IN
the/DT
top/NN
rank/NN
gene/NN
./.
====================
In/IN
the/DT
same/JJ
way/NN
,/,
we/PRP
can/MD
find/VB
the/DT
second/JJ
ranked/VBD
gene/NN
as/IN
λ/RB
continues/NNS
to/TO
be/VB
decreasing/VBG
./.
====================
Eventually/RB
,/,
we/PRP
can/MD
obtain/VB
a/DT
list/NN
of/IN
top/NN
ranked/VBD
genes/NNS
./.
====================
Since/IN
we/PRP
compared/VBD
a/DT
particular/JJ
number/NN
of/IN
top/NN
selected/VBN
genes/NNS
with/IN
the/DT
same/JJ
number/NN
of/IN
top/NN
significant/JJ
genes/NNS
computed/VBN
by/IN
multiple/JJ
testing/VBG
procedures/NNS
,/,
we/PRP
did/VBD
n't/RB
need/VBD
to/TO
find/VB
the/DT
optimal/JJ
λ/RB
value/NN
in/IN
the/DT
simulation/JJ
studies/NNS
and/CC
real/JJ
data/NNS
analysis/NN
./.
====================
Group/NN
lasso/NN
has/VBZ
been/VBN
widely/RB
applied/VBN
for/IN
analysis/NN
of/IN
high-dimensional/JJ
genomic/JJ
data/NNS
[/(
816/CD
]/)
./.
====================
We/PRP
used/VBD
an/DT
R/NN
package/NN
‘/CD
gglasso/RB
’/CD
for/IN
simulation/JJ
studies/NNS
and/CC
real/JJ
data/NNS
analysis/NN
./.
====================
Simulation/NN
studies/NNS
====================
In/IN
this/DT
simulation/JJ
study/NN
,/,
we/PRP
compared/VBD
true/JJ
positive/JJ
rates/NNS
of/IN
three/CD
group/NN
testing/VBG
procedures/NNS
and/CC
one/CD
selection/NN
procedure/NN
such/JJ
as/IN
PCA/NN
,/,
Hotelling/JJ
's/POS
T2/NN
test/NN
,/,
permutation/NN
test/NN
,/,
and/CC
group/NN
lasso/RB
selection/NN
procedure/NN
when/WRB
the/DT
same/JJ
number/NN
of/IN
genes/NNS
is/VBZ
identified/VBN
by/IN
four/CD
statistical/JJ
methods/NNS
./.
====================
We/PRP
conducted/VBD
two/CD
different/JJ
simulation/JJ
studies/NNS
,/,
where/WRB
the/DT
first/JJ
simulation/JJ
assumed/VBN
that/IN
all/DT
genes/NNS
are/VBP
independent/JJ
with/IN
each/DT
other/JJ
and/CC
the/DT
second/JJ
simulation/NN
assumed/VBN
that/IN
genes/NNS
are/VBP
correlated/VBN
with/IN
each/DT
other/JJ
according/VBG
to/TO
a/DT
given/VBN
network/NN
information/NN
./.
====================
In/IN
the/DT
first/JJ
simulation/NN
studies/NNS
,/,
we/PRP
assumed/VBD
that/IN
a/DT
single/JJ
gene/NN
consists/VBZ
of/IN
5/CD
genetic/JJ
sites/NNS
./.
====================
Numerical/JJ
data/NNS
of/IN
the/DT
five/CD
genetic/JJ
sites/NNS
within/IN
the/DT
same/JJ
gene/NN
were/VBD
generated/VBN
from/IN
a/DT
multivariate/JJ
normal/JJ
distribution/NN
of/IN
N/NN
(/(
µ/RB
,/,
Σ/NNP
)/)
,/,
where/WRB
a/DT
mean/JJ
vector/NN
µ/IN
has/VBZ
a/DT
different/JJ
value/NN
between/IN
cases/NNS
and/CC
controls/VBZ
if/IN
the/DT
gene/NN
is/VBZ
causal/JJ
,/,
but/CC
µ/RB
has/VBZ
the/DT
same/JJ
value/NN
between/IN
cases/NNS
and/CC
controls/VBZ
if/IN
the/DT
gene/NN
is/VBZ
noncausal/JJ
./.
====================
The/DT
covariance/NN
matrix/NN
Σ/NNP
represents/VBZ
a/DT
correlation/NN
pattern/NN
of/IN
the/DT
five/CD
genetic/JJ
sites/NNS
within/IN
the/DT
same/JJ
gene/NN
and/CC
we/PRP
assumed/VBD
an/DT
AR/NN
(/(
1/CD
)/)
correlation/NN
matrix/NN
,/,
i.e./FW
,/,
∑=/NNP
{/CD
σij/RB
}/CD
1≤i/NNP
,/,
j≤5=ρi−j/RB
,/,
where/WRB
ρ/RB
is/VBZ
a/DT
correlation/NN
coefficient/JJ
fixed/JJ
as/IN
ρ=0.3,0.5/CD
,/,
or/CC
0.7/CD
in/IN
the/DT
simulation/JJ
./.
====================
We/PRP
considered/VBD
1,000/CD
genes/NNS
so/RB
we/PRP
have/VBP
a/DT
total/JJ
of/IN
5,000/CD
genetic/JJ
sites/NNS
in/IN
the/DT
simulation/JJ
data/NNS
,/,
where/WRB
100/CD
cases/NNS
and/CC
100/CD
controls/NNS
were/VBD
generated/VBN
./.
====================
Only/RB
20/CD
genes/NNS
out/RP
of/IN
1,000/CD
genes/NNS
are/VBP
assumed/VBN
to/TO
be/VB
causal/JJ
./.
====================
Note/RB
that/DT
the/DT
simulated/JJ
1,000/CD
genes/NNS
are/VBP
independent/JJ
with/IN
each/DT
other/JJ
./.
====================
Three/CD
group/NN
testing/NN
procedures/NNS
were/VBD
applied/VBN
to/TO
individual/JJ
genes/NNS
and/CC
the/DT
p-values/NNS
of/IN
testing/VBG
the/DT
mean/JJ
difference/NN
between/IN
cases/NNS
and/CC
controls/VBZ
were/VBD
computed/VBN
for/IN
1,000/CD
genes/NNS
./.
====================
The/DT
p-values/NNS
of/IN
each/DT
testing/NN
procedure/NN
were/VBD
then/RB
listed/VBN
from/IN
the/DT
smallest/JJS
to/TO
the/DT
largest/JJS
./.
====================
Finally/RB
,/,
top/NN
20/CD
,/,
30/CD
,/,
and/CC
40/CD
genes/NNS
were/VBD
selected/VBN
for/IN
each/DT
testing/NN
procedure/NN
based/VBN
on/IN
the/DT
20/CD
,/,
30/CD
,/,
and/CC
40/CD
smallest/JJS
p-values/NNS
,/,
respectively/RB
./.
====================
In/IN
contrast/NN
,/,
group/NN
lasso/RB
procedure/NN
sequentially/RB
selects/NNS
the/DT
most/JJS
outcome-related/VBN
genes/NNS
as/IN
a/DT
tuning/JJ
parameter/NN
for/IN
sparsity/NN
is/VBZ
decreasing/VBG
./.
====================
Since/IN
we/PRP
can/MD
easily/RB
control/NN
the/DT
tuning/JJ
parameter/NN
value/NN
,/,
we/PRP
were/VBD
able/JJ
to/TO
select/VB
the/DT
top/NN
20/CD
,/,
30/CD
,/,
and/CC
40/CD
genes/NNS
./.
====================
True/JJ
positives/VBZ
rate/NN
of/IN
the/DT
selected/VBN
genes/NNS
from/IN
the/DT
four/CD
statistical/JJ
methods/NNS
were/VBD
computed/VBN
along/IN
with/IN
two/CD
different/JJ
values/NNS
of/IN
µ=0.3/NN
and/CC
0.4/CD
./.
====================
That/DT
is/VBZ
,/,
only/RB
20/CD
causal/JJ
genes/NNS
were/VBD
assumed/VBN
to/TO
have/VB
a/DT
mean/JJ
difference/NN
by/IN
either/CC
0.3/CD
or/CC
0.4/CD
between/IN
cases/NNS
and/CC
controls/VBZ
./.
====================
True/JJ
positive/JJ
rates/NNS
stand/CC
for/IN
the/DT
proportion/NN
of/IN
correctly/RB
identified/VBN
genes/NNS
among/IN
the/DT
20/CD
causal/JJ
genes/NNS
./.
====================
The/DT
simulation/JJ
was/VBD
repeated/VBN
100/CD
times/NNS
and/CC
averaged/JJ
true/JJ
positive/JJ
rates/NNS
of/IN
four/CD
statistical/JJ
methods/NNS
over/IN
100/CD
simulation/NN
replications/NNS
were/VBD
summarized/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
In/IN
Fig/NN
./.
====================
1/CD
,/,
it/PRP
appears/VBZ
that/IN
all/DT
of/IN
true/JJ
positive/JJ
rates/NNS
are/VBP
overall/JJ
increased/VBD
as/IN
the/DT
mean/JJ
difference/NN
is/VBZ
increasing/VBG
and/CC
the/DT
correlation/NN
coefficient/JJ
is/VBZ
decreasing/VBG
./.
====================
In/IN
high-dimensional/JJ
data/NNS
analysis/NN
,/,
it/PRP
is/VBZ
often/RB
observed/VBN
that/IN
detection/NN
power/JJR
is/VBZ
decreased/VBN
due/JJ
to/TO
highly/RB
correlated/VBD
variables/NNS
./.
====================
We/PRP
can/MD
see/VB
the/DT
similar/JJ
result/NN
of/IN
decreased/VBN
true/JJ
positive/JJ
rates/NNS
for/IN
highly/RB
correlated/VBD
genetic/JJ
sites/NNS
./.
====================
When/WRB
we/PRP
compared/VBD
four/CD
statistical/JJ
methods/NNS
,/,
both/CC
PCA/NN
and/CC
permutation/NN
test/NN
seem/VBP
to/TO
have/VB
the/DT
largest/JJS
true/JJ
positive/JJ
rates/NNS
in/IN
all/DT
simulation/JJ
settings/NNS
,/,
while/IN
Hotelling/JJ
's/POS
T2/NN
test/NN
show/VBP
the/DT
lowest/JJS
true/JJ
positive/JJ
rates/NNS
in/IN
all/DT
settings/NNS
./.
====================
The/DT
true/JJ
positive/JJ
rates/NNS
of/IN
group/NN
lasso/RB
procedure/NN
seem/VBP
to/TO
be/VB
higher/JJR
than/IN
those/DT
of/IN
Hotelling/JJ
's/POS
T2/NN
test/NN
,/,
but/CC
slightly/RB
lower/JJR
than/IN
those/DT
of/IN
both/DT
PCA/NN
and/CC
permutation/NN
test/NN
./.
====================
Consequently/RB
,/,
we/PRP
can/MD
conclude/VB
that/IN
group/NN
lasso/RB
procedure/NN
shows/VBZ
similar/JJ
selection/NN
performance/NN
as/IN
the/DT
group/NN
hypothesis/NN
testing/NN
procedures/NNS
in/IN
the/DT
first/JJ
simulation/NN
study/NN
./.
====================
In/IN
the/DT
second/JJ
simulation/NN
study/NN
,/,
we/PRP
generated/VBD
1,000/CD
genes/NNS
where/WRB
each/DT
100/CD
genes/NNS
are/VBP
truly/RB
correlated/VBD
with/IN
each/DT
other/JJ
according/VBG
to/TO
the/DT
simulated/JJ
genetic/JJ
network/NN
in/IN
Fig/NN
./.
====================
2/CD
./.
====================
So/RB
,/,
we/PRP
have/VBP
10/CD
network/NN
groups/NNS
each/DT
of/IN
which/WDT
consists/VBZ
of/IN
100/CD
genes/NNS
./.
====================
Similar/JJ
to/TO
the/DT
first/JJ
simulation/JJ
study/NN
,/,
genetic/JJ
data/NNS
was/VBD
generated/VBN
from/IN
N/NN
(/(
µ/RB
,/,
Σ/NNP
)/)
,/,
where/WRB
the/DT
covariance/NN
matrix/NN
Σ/NNP
is/VBZ
an/DT
inverse/JJ
of/IN
a/DT
precision/NN
matrix/NN
Ω/NNP
In/IN
a/DT
Gaussian/JJ
graphical/JJ
model/NN
[/(
17/CD
]/)
,/,
nonzero/RB
entries/VBZ
of/IN
the/DT
precision/NN
matrix/NN
correspond/VBP
to/TO
links/NNS
between/IN
two/CD
genes/NNS
of/IN
a/DT
network/NN
graph/NN
./.
====================
Therefore/RB
,/,
we/PRP
could/MD
obtain/VB
the/DT
precision/NN
matrix/NN
Ω/NN
according/VBG
to/TO
the/DT
given/VBN
network/NN
in/IN
Fig/NN
./.
====================
2/CD
in/IN
the/DT
same/JJ
way/NN
described/VBN
[/(
1218/CD
]/)
./.
====================
Our/PRP$
simulation/JJ
data/NNS
consists/VBZ
of/IN
100/CD
cases/NNS
and/CC
100/CD
controls/NNS
over/IN
1,000/CD
genes/NNS
,/,
where/WRB
only/RB
45/CD
genes/NNS
within/IN
the/DT
same/JJ
network/NN
have/VBP
a/DT
different/JJ
mean/NN
µ/RB
between/IN
cases/NNS
and/CC
controls/VBZ
./.
====================
Let/NN
us/PRP
denote/VBP
the/DT
j-th/NN
gene/NN
by/IN
χj/JJ
./.
====================
Since/IN
our/PRP$
simulation/NN
study/NN
should/MD
be/VB
conducted/VBN
for/IN
genetic/JJ
sites/NNS
with/IN
a/DT
group/NN
structure/NN
,/,
we/PRP
additionally/RB
generated/VBN
10/CD
genetic/JJ
sites/NNS
for/IN
each/DT
gene/NN
./.
====================
If/IN
the/DT
first/JJ
N/NN
genetic/JJ
sites/NNS
among/IN
10/CD
sites/NNS
are/VBP
causal/JJ
and/CC
the/DT
other/JJ
10/CD
-/:
N/NN
genetic/JJ
sites/NNS
are/VBP
noncasual/JJ
,/,
the/DT
N/NN
sites/NNS
of/IN
the/DT
the/DT
j-th/NN
gene/NN
were/VBD
generated/VBN
such/JJ
that/IN
χjk/VBP
=/JJ
χj/RB
+/CC
N/NN
(/(
0/CD
,/,
σ2/RB
)/)
,/,
k/RB
=/JJ
1/CD
,/,
2/CD
,/,
…/NNP
,/,
N/NN
and/CC
χjk/RB
=/JJ
N/NN
(/(
0/CD
,/,
σ2/RB
)/)
for/IN
k/JJ
=/JJ
N/NN
+/CC
1/CD
,/,
…/NNP
,/,
10/CD
./.
====================
Finally/RB
,/,
we/PRP
have/VBP
a/DT
total/JJ
of/IN
10,000/CD
genetic/JJ
sites/NNS
with/IN
200/CD
samples/NNS
./.
====================
In/IN
the/DT
simulation/JJ
,/,
we/PRP
discarded/VBD
all/DT
simulated/JJ
genes/NNS
χj/WDT
for/IN
j/NN
=/JJ
1/CD
,/,
2/CD
,/,
…/CD
,/,
1,000/CD
./.
====================
Instead/RB
,/,
we/PRP
used/VBD
only/RB
10,000/CD
genetic/JJ
sites/NNS
where/WRB
each/DT
10/CD
sites/NNS
consist/VBP
of/IN
one/CD
gene/NN
./.
====================
In/IN
this/DT
simulation/JJ
setting/VBG
,/,
10/CD
genetic/JJ
sites/NNS
within/IN
the/DT
same/JJ
gene/NN
are/VBP
not/RB
only/RB
correlated/VBD
with/IN
each/DT
other/JJ
,/,
but/CC
they/PRP
are/VBP
also/RB
correlated/VBD
with/IN
the/DT
other/JJ
10/CD
genetic/JJ
sites/NNS
within/IN
the/DT
different/JJ
genes/NNS
that/WDT
are/VBP
linked/VBN
with/IN
each/DT
other/JJ
according/VBG
to/TO
the/DT
genetic/JJ
network/NN
./.
====================
We/PRP
also/RB
applied/VBD
four/CD
statistical/JJ
methods/NNS
used/VBN
in/IN
the/DT
first/JJ
simulation/NN
study/NN
./.
====================
We/PRP
fixed/VBD
the/DT
number/NN
of/IN
causal/JJ
genetic/JJ
sites/NNS
per/IN
gene/NN
as/IN
N/NN
=/JJ
2/CD
,/,
5/CD
,/,
or/CC
10/CD
./.
====================
Since/IN
only/RB
45/CD
genes/NNS
are/VBP
causal/JJ
,/,
the/DT
number/NN
of/IN
causal/JJ
sites/NNS
is/VBZ
90/CD
,/,
225/CD
,/,
or/CC
450/CD
among/IN
10,000/CD
sites/NNS
,/,
respectively/RB
./.
====================
The/DT
standard/JJ
deviation/NN
σ/RB
to/TO
control/VB
a/DT
noise/JJ
level/NN
was/VBD
set/NN
to/TO
be/VB
1.5/CD
,/,
2/CD
,/,
or/CC
2.5/CD
./.
====================
Higher/JJ
standard/JJ
deviation/NN
is/VBZ
likely/JJ
to/TO
produce/VB
stronger/JJR
noises/NNS
,/,
so/RB
true/JJ
positive/JJ
rates/NNS
are/VBP
expected/VBN
to/TO
be/VB
decreased/VBN
./.
====================
Simulation/NN
was/VBD
repeated/VBN
100/CD
times/NNS
and/CC
averaged/JJ
true/JJ
positive/JJ
rates/NNS
of/IN
top/NN
10/CD
genes/NNS
to/TO
top/VB
100/CD
genes/NNS
selected/VBN
by/IN
four/CD
methods/NNS
are/VBP
summarized/VBN
in/IN
Fig/NN
./.
====================
3/CD
./.
====================
In/IN
Fig/NN
./.
====================
3/CD
,/,
PCA/NN
overall/JJ
shows/VBZ
the/DT
best/JJS
selection/NN
performance/NN
except/IN
when/WRB
the/DT
noise/JJ
level/NN
is/VBZ
either/CC
moderate/JJ
or/CC
strong/JJ
,/,
and/CC
the/DT
number/NN
of/IN
causal/JJ
genetic/JJ
sites/NNS
is/VBZ
small/JJ
,/,
i.e./FW
,/,
N/NN
=/JJ
2/CD
and/CC
σ=/JJ
2/CD
or/CC
2.5/CD
./.
====================
As/IN
the/DT
number/NN
of/IN
causal/JJ
sites/NNS
in/IN
a/DT
gene/NN
is/VBZ
decreasing/VBG
,/,
the/DT
true/JJ
positive/JJ
rates/NNS
of/IN
three/CD
group/NN
testing/NN
procedures/NNS
seem/VBP
to/TO
be/VB
decreasing/VBG
together/RB
./.
====================
However/RB
,/,
we/PRP
can/MD
see/VB
that/DT
the/DT
true/JJ
positive/JJ
rates/NNS
of/IN
group/NN
lasso/RB
are/VBP
almost/RB
the/DT
same/JJ
regardless/RB
of/IN
the/DT
number/NN
of/IN
causal/JJ
sites/NNS
in/IN
a/DT
gene/NN
./.
====================
As/IN
we/PRP
mentioned/VBD
earlier/RBR
,/,
group/NN
lasso/RB
enforces/VBZ
the/DT
regression/NN
coefficients/NNS
of/IN
genetic/JJ
sites/NNS
in/IN
the/DT
selected/VBN
genes/NNS
to/TO
be/VB
nonzero/JJ
even/RB
if/IN
only/RB
a/DT
few/JJ
genetic/JJ
sites/NNS
are/VBP
causal/JJ
and/CC
majority/NN
is/VBZ
noncausal/JJ
./.
====================
In/IN
this/DT
reason/NN
,/,
the/DT
selection/NN
performance/NN
of/IN
group/NN
lasso/RB
does/VBZ
not/RB
affected/VBN
by/IN
the/DT
number/NN
of/IN
causal/JJ
and/CC
noncausal/JJ
sites/NNS
in/IN
the/DT
same/JJ
gene/NN
./.
====================
When/WRB
all/DT
of/IN
genetic/JJ
sites/NNS
in/IN
the/DT
same/JJ
gene/NN
are/VBP
causal/JJ
(/(
N/NN
=/JJ
10/CD
)/)
,/,
both/CC
PCA/NN
and/CC
permutation/NN
test/NN
overwhelm/IN
the/DT
other/JJ
two/CD
methods/NNS
./.
====================
Since/IN
computation/NN
of/IN
the/DT
test/NN
statistics/NNS
of/IN
two/CD
methods/NNS
is/VBZ
based/VBN
on/IN
individual/JJ
genetic/JJ
sites/NNS
,/,
they/PRP
should/MD
be/VB
statistically/RB
powerful/JJ
when/WRB
all/DT
of/IN
sites/NNS
in/IN
the/DT
same/JJ
gene/NN
are/VBP
causal/JJ
./.
====================
In/IN
the/DT
second/JJ
simulation/NN
,/,
the/DT
Hotelling/JJ
's/POS
T2/NN
test/NN
shows/VBZ
the/DT
worst/NN
selection/NN
of/IN
true/JJ
positives/VBZ
in/IN
all/DT
simulation/JJ
settings/NNS
./.
====================
This/DT
is/VBZ
due/JJ
to/TO
relatively/RB
high/JJ
correlation/NN
among/IN
genetic/JJ
sites/NNS
in/IN
the/DT
same/JJ
genes/NNS
./.
====================
We/PRP
have/VBP
already/RB
seen/VBN
that/IN
the/DT
true/JJ
positive/JJ
rates/NNS
of/IN
Hotelling/JJ
's/POS
T2/NN
test/NN
were/VBD
drastically/RB
decreased/VBD
as/IN
the/DT
correlation/NN
was/VBD
increasing/VBG
in/IN
the/DT
first/JJ
simulation/NN
study/NN
./.
====================
Analysis/NN
of/IN
ovarian/JJ
cancer/NN
DNA/NN
methylation/NN
data/NNS
====================
Next/RB
,/,
we/PRP
applied/VBD
four/CD
statistical/JJ
methods/NNS
to/TO
real/JJ
ovarian/JJ
cancer/NN
DNA/NN
methylation/NN
data/NNS
./.
====================
Ovarian/JJ
cancer/NN
DNA/NN
methylation/NN
data/NNS
generated/VBD
from/IN
Illumina/NN
Infinium/NN
Human-Methylation27K/JJ
Beadchip/NN
has/VBZ
been/VBN
already/RB
applied/VBN
to/TO
identify/VB
CpG/NN
sites/NNS
and/CC
genes/NNS
associated/VBN
with/IN
ovarian/JJ
cancer/NN
from/IN
some/DT
different/JJ
studies/NNS
[/(
192021/CD
]/)
./.
====================
The/DT
methylation/NN
data/NNS
set/VBP
consists/VBZ
of/IN
20,461/CD
CpG/NN
sites/NNS
from/IN
12,770/CD
genes/NNS
with/IN
152/CD
controls/NNS
and/CC
119/CD
cases/NNS
./.
====================
Many/JJ
genes/NNS
have/VBP
either/CC
one/CD
or/CC
two/CD
CpG/NN
sites/NNS
and/CC
some/DT
genes/NNS
have/VBP
up/RB
to/TO
9/CD
CpG/NN
sites/NNS
./.
====================
Since/IN
our/PRP$
four/CD
statistical/JJ
methods/NNS
can/MD
be/VB
applied/VBN
to/TO
genomic/JJ
data/NNS
with/IN
a/DT
group/NN
structure/NN
,/,
and/CC
our/PRP$
main/JJ
goal/NN
of/IN
this/DT
study/NN
is/VBZ
to/TO
compare/VB
group/NN
testing/VBG
procedures/NNS
with/IN
group/NN
selection/NN
procedure/NN
,/,
we/PRP
excluded/VBD
genes/NNS
that/WDT
have/VBP
only/RB
one/CD
CpG/NN
site/NN
in/IN
the/DT
analysis/NN
./.
====================
So/RB
,/,
we/PRP
ended/VBD
up/IN
with/IN
14,627/CD
CpG/NN
sites/NNS
from/IN
6,936/CD
genes/NNS
which/WDT
have/VBP
at/IN
least/JJS
two/CD
CpG/NN
sites/NNS
./.
====================
In/IN
the/DT
exactly/RB
same/JJ
way/NN
used/VBN
in/IN
the/DT
simulation/JJ
studies/NNS
,/,
we/PRP
identified/VBD
top/NN
20/CD
genes/NNS
for/IN
each/DT
method/NN
./.
====================
Table/JJ
1/CD
shows/VBZ
the/DT
top/NN
20/CD
genes/NNS
and/CC
their/PRP$
p-values/NNS
computed/VBN
by/IN
PCA/NN
and/CC
Hotelling/JJ
's/POS
T2/NN
test/NN
./.
====================
Also/RB
,/,
20/CD
selected/VBN
genes/NNS
by/IN
group/NN
lasso/RB
procedure/NN
are/VBP
included/VBN
in/IN
the/DT
table/JJ
./.
====================
For/IN
the/DT
permutation/NN
test/NN
,/,
we/PRP
permuted/VBD
the/DT
data/NNS
over/IN
1,000,000/CD
times/NNS
,/,
but/CC
we/PRP
found/VBD
that/IN
the/DT
empirical/JJ
p-values/NNS
of/IN
246/CD
genes/NNS
are/VBP
still/RB
less/RBR
than/IN
10–7/CD
./.
====================
Due/IN
to/TO
time/NN
limit/VB
,/,
we/PRP
can/MD
not/RB
reduce/VB
down/RB
the/DT
number/NN
of/IN
genes/NNS
in/IN
the/DT
top/NN
list/NN
of/IN
permutation/NN
test/NN
anymore/DT
./.
====================
Therefore/RB
,/,
we/PRP
had/VBD
to/TO
finalize/VB
with/IN
top/NN
246/CD
genes/NNS
detected/VBN
by/IN
permutation/NN
test/NN
./.
====================
For/IN
each/DT
statistical/JJ
method/NN
,/,
Fig/NN
./.
====================
4/CD
summarizes/VBZ
the/DT
number/NN
of/IN
overlapped/VBN
genes/NNS
among/IN
top/NN
20/CD
genes/NNS
by/IN
the/DT
other/JJ
three/CD
methods/NNS
./.
====================
In/IN
Fig/NN
./.
====================
4/CD
,/,
it/PRP
appears/VBZ
that/IN
15/CD
genes/NNS
in/IN
the/DT
top/NN
20/CD
list/NN
of/IN
PCA/NN
is/VBZ
also/RB
in/IN
the/DT
top/NN
20/CD
list/NN
of/IN
Hotelling/JJ
's/POS
T2/NN
test/NN
,/,
while/IN
only/RB
2/CD
genes/NNS
in/IN
the/DT
top/NN
20/CD
list/NN
of/IN
PCA/NN
is/VBZ
in/IN
the/DT
top/NN
20/CD
list/NN
of/IN
group/NN
lasso/RB
./.
====================
Similarly/RB
,/,
we/PRP
can/MD
see/VB
that/DT
only/RB
3/CD
genes/NNS
in/IN
the/DT
top/NN
20/CD
list/NN
of/IN
Hotelling/JJ
's/POS
T2/NN
test/NN
is/VBZ
in/IN
the/DT
top/NN
20/CD
list/NN
of/IN
group/NN
lasso/RB
./.
====================
Top/RB
246/CD
genes/NNS
detected/VBN
by/IN
permutation/NN
test/NN
include/VBP
all/DT
of/IN
the/DT
20/CD
genes/NNS
detected/VBN
by/IN
both/CC
PCA/NN
and/CC
Hotelling/JJ
's/POS
T2/NN
test/NN
,/,
but/CC
only/RB
7/CD
genes/NNS
among/IN
the/DT
246/CD
genes/NNS
are/VBP
overlapped/VBN
with/IN
top/NN
20/CD
genes/NNS
selected/VBN
by/IN
group/NN
lasso/RB
./.
====================
This/DT
result/NN
indicates/VBZ
that/IN
genes/NNS
selected/VBN
by/IN
group/NN
lasso/RB
are/VBP
quite/RB
different/JJ
from/IN
genes/NNS
detected/VBN
by/IN
three/CD
group/NN
testing/NN
procedures/NNS
./.
====================
Next/RB
,/,
we/PRP
identified/VBD
top/NN
246/CD
genes/NNS
by/IN
each/DT
of/IN
four/CD
different/JJ
statistical/JJ
methods/NNS
since/IN
the/DT
minimum/JJ
number/NN
of/IN
genes/NNS
detected/VBN
by/IN
permutation/NN
test/NN
is/VBZ
246/CD
./.
====================
Fig/NN
./.
====================
5/CD
summarizes/VBZ
the/DT
number/NN
of/IN
overlapped/VBN
genes/NNS
among/IN
246/CD
genes/NNS
by/IN
the/DT
other/JJ
three/CD
methods/NNS
./.
====================
It/PRP
seems/VBZ
that/DT
three/CD
group/NN
testing/VBG
procedures/NNS
of/IN
PCA/NN
,/,
Hotelling/JJ
's/POS
T2/NN
test/NN
and/CC
permutation/NN
test/NN
have/VBP
from/IN
164/CD
(/(
66.67/CD
%/NN
)/)
to/TO
205/CD
(/(
83.73/CD
%/NN
)/)
overlapped/VBD
genes/NNS
with/IN
each/DT
other/JJ
./.
====================
In/IN
contrast/NN
,/,
group/NN
lasso/RB
selection/NN
procedure/NN
have/VBP
only/RB
24/CD
(/(
9.76/CD
%/NN
)/)
to/TO
31/CD
(/(
12.60/CD
%/NN
)/)
overlapped/VBD
genes/NNS
with/IN
three/CD
group/NN
testing/NN
procedures/NNS
./.
====================
In/IN
this/DT
result/NN
,/,
we/PRP
can/MD
conclude/VB
that/IN
most/JJS
of/IN
genes/NNS
selected/VBN
by/IN
group/NN
lasso/RB
are/VBP
very/RB
different/JJ
from/IN
genes/NNS
detected/VBN
by/IN
multiple/JJ
group/NN
testing/VBG
procedures/NNS
in/IN
high-dimensional/JJ
DNA/NN
methlyation/NN
data/NNS
analysis/NN
./.
====================
In/IN
the/DT
first/JJ
simulation/NN
study/NN
three/CD
group/NN
testing/NN
procedures/NNS
and/CC
group/NN
lasso/RB
selection/NN
procedure/NN
show/VBP
very/RB
similar/JJ
selection/NN
performance/NN
./.
====================
However/RB
,/,
selection/NN
performance/NN
of/IN
four/CD
methods/NNS
was/VBD
quite/RB
different/JJ
from/IN
each/DT
other/JJ
in/FW
the/DT
second/JJ
simulation/NN
study/NN
./.
====================
We/PRP
demonstrated/VBD
that/IN
true/JJ
positive/JJ
selection/NN
could/MD
vary/VB
on/IN
the/DT
number/NN
of/IN
causal/JJ
sites/NNS
and/CC
the/DT
noise/JJ
level/NN
./.
====================
In/IN
analysis/NN
of/IN
ovarian/JJ
cancer/NN
DNA/NN
methylation/NN
data/NNS
,/,
we/PRP
found/VBD
that/IN
group/NN
lasso/RB
identified/VBN
quite/RB
different/JJ
genes/NNS
,/,
compared/VBN
with/IN
three/CD
group/NN
testing/NN
procedures/NNS
./.
====================
In/IN
general/JJ
,/,
regularization/NN
procedures/NNS
like/IN
group/NN
lasso/RB
are/VBP
known/VBN
as/IN
a/DT
good/JJ
alternative/JJ
method/NN
to/TO
testing/VBG
procedures/NNS
when/WRB
we/PRP
identify/VBP
disease/NN
or/CC
trait/VBP
associated/VBN
genes/NNS
with/IN
high-dimensional/JJ
genomic/JJ
data/NNS
,/,
where/WRB
the/DT
number/NN
of/IN
genes/NNS
far/RB
exceeds/VBZ
the/DT
number/NN
of/IN
samples/NNS
./.
====================
However/RB
,/,
our/PRP$
investigation/NN
found/VBN
that/IN
many/JJ
genes/NNS
selected/VBN
by/IN
group/NN
lasso/RB
are/VBP
rarely/RB
overlapped/VBD
with/IN
genes/NNS
detected/VBN
by/IN
three/CD
group/NN
testing/NN
procedures/NNS
,/,
which/WDT
detected/VBD
many/JJ
overlapped/VBD
genes/NNS
./.
====================
The/DT
similar/JJ
situation/NN
was/VBD
observed/VBN
when/WRB
the/DT
number/NN
of/IN
causal/JJ
sites/NNS
is/VBZ
small/JJ
and/CC
the/DT
noise/JJ
level/NN
is/VBZ
relatively/RB
large/JJ
in/IN
our/PRP$
second/JJ
simulation/NN
study/NN
./.
====================
In/IN
that/DT
case/NN
,/,
true/JJ
positive/JJ
rates/NNS
of/IN
group/NN
lasso/RB
are/VBP
much/RB
higher/JJR
than/IN
those/DT
of/IN
three/CD
group/NN
testing/VBG
procedures/NNS
,/,
where/WRB
three/CD
testing/VBG
procedures/NNS
shows/VBZ
the/DT
almost/RB
same/JJ
selection/NN
performance/NN
./.
====================
In/IN
real/JJ
DNA/NN
methylation/NN
data/NNS
multiple/JJ
genes/NNS
are/VBP
usually/RB
highly/RB
correlated/VBD
with/IN
each/DT
other/JJ
./.
====================
Moreover/RB
,/,
the/DT
number/NN
of/IN
causal/JJ
sites/NNS
could/MD
be/VB
small/JJ
and/CC
the/DT
noise/JJ
level/NN
could/MD
be/VB
large/JJ
./.
====================
But/CC
,/,
further/RB
biological/JJ
investigation/NN
with/IN
genes/NNS
selected/VBN
by/IN
group/NN
lasso/RB
should/MD
be/VB
conducted/VBN
to/TO
figure/NN
out/IN
the/DT
main/JJ
reason/NN
of/IN
this/DT
big/NN
discrepancy/NN
between/IN
group/NN
lasso/RB
and/CC
group/NN
tests/NNS
in/IN
analysis/NN
of/IN
DNA/NN
methylation/NN
data/NNS
./.
====================
In/IN
this/DT
article/NN
,/,
we/PRP
compared/VBD
group/NN
testing/NN
procedures/NNS
with/IN
group/NN
lasso/RB
selection/NN
procedure/NN
when/WRB
high-dimensional/JJ
genomic/JJ
data/NNS
with/IN
a/DT
group/NN
structure/NN
are/VBP
used/VBN
for/IN
case-control/JJ
genetic/JJ
association/NN
studies/NNS
./.
====================
In/IN
statistics/NNS
,/,
hypothesis/NN
testing/NN
and/CC
variable/JJ
selection/NN
are/VBP
regarded/VBN
as/IN
totally/RB
different/JJ
statistical/JJ
methods/NNS
since/IN
their/PRP$
objectives/NNS
are/VBP
different/JJ
from/IN
each/DT
other/JJ
./.
====================
Therefore/RB
,/,
the/DT
comparison/NN
of/IN
these/DT
two/CD
statistical/JJ
approaches/NNS
has/VBZ
not/RB
been/VBN
studied/VBN
much/RB
./.
====================
However/RB
,/,
in/IN
genetic/JJ
association/NN
studies/NNS
with/IN
high-dimensional/JJ
genomic/JJ
data/NNS
,/,
both/CC
testing/VBG
and/CC
selection/NN
procedures/NNS
have/VBP
the/DT
same/JJ
goal/NN
which/WDT
is/VBZ
to/TO
identify/VB
genes/NNS
of/IN
genetic/JJ
regions/NNS
that/IN
are/VBP
associated/VBN
with/IN
either/CC
a/DT
disease/NN
or/CC
a/DT
trait/JJ
./.
====================
Particularly/RB
,/,
many/JJ
types/NNS
of/IN
high-dimensional/JJ
genomic/JJ
data/NNS
consist/VBP
of/IN
multiple/JJ
groups/NNS
where/WRB
each/DT
gene/NN
or/CC
each/DT
genetic/JJ
region/NN
contains/VBZ
some/DT
genetic/JJ
sites/NNS
or/CC
variants/NNS
./.
====================
So/RB
,/,
our/PRP$
research/NN
focused/VBN
on/IN
the/DT
comparison/NN
of/IN
group/NN
testing/NN
procedures/NNS
and/CC
group/NN
lasso/RB
selection/NN
procedure/NN
./.
====================
In/IN
simulation/NN
studies/NNS
,/,
we/PRP
found/VBD
that/IN
the/DT
selection/NN
performance/NN
of/IN
group/NN
lasso/RB
and/CC
group/NN
testing/NN
procedures/NNS
could/MD
be/VB
similar/JJ
or/CC
very/RB
different/JJ
from/IN
each/DT
other/JJ
./.
====================
It/PRP
depends/VBZ
on/IN
data/NNS
structure/NN
such/JJ
as/IN
correlation/NN
strength/NN
and/CC
patterns/NNS
among/IN
genes/NNS
,/,
the/DT
number/NN
of/IN
causal/JJ
sites/NNS
in/IN
a/DT
gene/NN
and/CC
noise/RB
levels/NNS
./.
====================
In/IN
real/JJ
data/NNS
analysis/NN
,/,
it/PRP
was/VBD
surprising/VBG
that/IN
group/NN
lasso/RB
identified/VBN
many/JJ
different/JJ
genes/NNS
that/WDT
are/VBP
not/RB
detected/VBN
by/IN
group/NN
testing/VBG
procedures/NNS
in/IN
ovarian/JJ
cancer/NN
association/NN
similar/JJ
or/CC
very/RB
different/JJ
from/IN
each/DT
other/JJ
./.
====================
It/PRP
depends/VBZ
on/IN
data/NNS
structure/NN
such/JJ
as/IN
correlation/NN
strength/NN
and/CC
patterns/NNS
among/IN
genes/NNS
,/,
the/DT
number/NN
of/IN
causal/JJ
sites/NNS
in/IN
a/DT
gene/NN
and/CC
noise/RB
levels/NNS
./.
====================
In/IN
real/JJ
data/NNS
analysis/NN
,/,
it/PRP
was/VBD
surprising/VBG
that/IN
group/NN
lasso/RB
identified/VBN
many/JJ
different/JJ
genes/NNS
that/WDT
are/VBP
not/RB
detected/VBN
by/IN
group/NN
testing/VBG
procedures/NNS
in/IN
ovarian/JJ
cancer/NN
association/NN
studies/NNS
of/IN
DNA/NN
methylation/NN
data/NNS
./.
====================
Although/IN
group/NN
lasso/RB
is/VBZ
known/VBN
as/IN
one/CD
of/IN
the/DT
most/JJS
commonly/RB
used/VBN
selection/NN
methods/NNS
in/IN
statistics/NNS
when/WRB
the/DT
number/NN
of/IN
variables/NNS
is/VBZ
much/RB
greater/JJR
than/IN
a/DT
sample/JJ
size/NN
,/,
it/PRP
shows/VBZ
unexpected/JJ
selection/NN
results/VBZ
in/IN
ovarian/JJ
cancer/NN
data/NNS
analysis/NN
./.
====================
In/IN
contrast/NN
,/,
multiple/JJ
group/NN
testing/NN
procedures/NNS
including/VBG
PCA/NN
,/,
Hotelling/JJ
's/POS
T2/NN
test/NN
and/CC
permutation/NN
test/NN
identified/VBD
almost/RB
the/DT
same/JJ
genes/NNS
associated/VBN
with/IN
ovarian/JJ
cancer/NN
./.
====================
Since/IN
multiple/JJ
group/NN
testing/VBG
procedures/NNS
are/VBP
still/RB
the/DT
most/JJS
popular/JJ
method/NN
for/IN
medical/JJ
doctors/NNS
and/CC
geneticists/NNS
to/TO
apply/RB
for/IN
high-dimensional/JJ
genomic/JJ
data/NNS
with/IN
a/DT
group/NN
structure/NN
,/,
we/PRP
might/MD
need/RB
to/TO
further/RBR
investigate/VB
the/DT
validity/NN
of/IN
group/NN
lasso/RB
selection/NN
procedure/NN
in/IN
genetic/JJ
association/NN
studies/NNS
./.
====================
In/IN
future/JJ
study/NN
,/,
our/PRP$
investigation/NN
will/MD
focus/VB
on/IN
finding/NN
additional/JJ
reasons/NNS
that/DT
we/PRP
had/VBD
many/JJ
genes/NNS
detected/VBN
by/IN
group/NN
test/NN
procedures/NNS
but/CC
missed/VBD
by/IN
group/NN
lasso/RB
in/IN
ovarian/JJ
cancer/NN
data/NNS
./.
====================
Averaged/JJ
true/JJ
positive/JJ
rates/NNS
of/IN
top/NN
20/CD
,/,
30/CD
,/,
and/CC
40/CD
genes/NNS
detected/VBN
by/IN
principal/JJ
component/NN
analysis/NN
(/(
PCA/NN
)/)
,/,
Hotelling/JJ
's/POS
T2/NN
test/NN
(/(
Hotel/NNP
)/)
,/,
permutation/NN
test/NN
(/(
Permut/NN
)/)
,/,
and/CC
group/NN
lasso/RB
are/VBP
displayed/VBN
along/IN
with/IN
a/DT
different/JJ
correlation/NN
coefficient/JJ
ρ/RB
of/IN
0.3/CD
,/,
0.5/CD
,/,
and/CC
0.7/CD
,/,
and/CC
a/DT
different/JJ
mean/JJ
difference/NN
µ/IN
of/IN
0.3/CD
and/CC
0.4/CD
between/IN
cases/NNS
and/CC
controls/VBZ
./.
====================
An/DT
example/NN
of/IN
a/DT
simulated/JJ
network/NN
graph/NN
with/IN
100/CD
genes/NNS
used/VBN
in/IN
the/DT
second/JJ
simulation/NN
study/NN
is/VBZ
present/JJ
./.
====================
The/DT
colored/JJ
45/CD
genes/NNS
are/VBP
assumed/VBN
to/TO
be/VB
causal/JJ
genes/NNS
./.
====================
Averaged/JJ
true/JJ
positive/JJ
rates/NNS
of/IN
principal/JJ
component/NN
analysis/NN
(/(
PCA/NN
)/)
,/,
Hotelling/JJ
's/POS
T2/NN
test/RB
,/,
permutation/NN
test/NN
,/,
and/CC
group/NN
lasso/RB
are/VBP
displayed/VBN
along/IN
with/IN
a/DT
different/JJ
number/NN
of/IN
selected/VBN
genes/NNS
when/WRB
the/DT
number/NN
of/IN
causal/JJ
genetic/JJ
sites/NNS
(/(
N/NN
)/)
among/IN
10/CD
sites/NNS
in/IN
a/DT
gene/NN
is/VBZ
2/CD
,/,
5/CD
,/,
or/CC
10/CD
,/,
and/CC
the/DT
standard/JJ
deviation/NN
of/IN
an/DT
error/JJ
terms/NNS
(/(
σ/RB
)/)
to/TO
control/JJ
a/DT
noise/JJ
level/NN
is/VBZ
1.5/CD
,/,
2/CD
,/,
or/CC
2.5/CD
./.
====================
The/DT
number/NN
of/IN
overlapped/VBN
genes/NNS
and/CC
non-overlapped/JJ
genes/NNS
in/IN
the/DT
top/NN
20/CD
lists/NNS
of/IN
principal/JJ
component/NN
analysis/NN
(/(
PCA/NN
)/)
,/,
Hotelling/JJ
's/POS
T2/NN
test/NN
,/,
permutation/NN
test/NN
,/,
and/CC
group/NN
lasso/RB
are/VBP
displayed/VBN
in/IN
analysis/NN
of/IN
ovarian/JJ
cancer/NN
DNA/NN
methylation/NN
data/NNS
./.
====================
The/DT
number/NN
of/IN
overlapped/VBN
genes/NNS
and/CC
non-overlapped/JJ
genes/NNS
in/IN
the/DT
top/NN
246/CD
lists/NNS
of/IN
principal/JJ
component/NN
analysis/NN
(/(
PCA/NN
)/)
,/,
Hotelling/JJ
's/POS
T2/NN
test/NN
,/,
permutation/NN
test/NN
,/,
and/CC
group/NN
lasso/RB
are/VBP
displayed/VBN
in/IN
analysis/NN
of/IN
ovarian/JJ
cancer/NN
DNA/NN
methylation/NN
data/NNS
./.
====================
Top/RB
20/CD
gene/NN
lists/NNS
and/CC
their/PRP$
p-values/NNS
detected/VBN
by/IN
PCA/NN
and/CC
Hotelling/JJ
's/POS
T2/NN
test/NN
and/CC
top/NN
20/CD
gene/NN
list/NN
selected/VBN
by/IN
group/NN
lasso/RB
====================
